NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Resumen
Palabras clave
Ipilimumab; Mesotelioma pleural maligno; Vacuna de telomerasa
Citación recomendada
Drageset Haakensen V, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, et al. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med. 2021 May 31;19:232.
Audiencia
Professionals
Usar este identificador para citar y/o enlazar este documento
https://hdl.handle.net/11351/7211Este elemento aparece en las siguientes colecciones
- HVH - Articles científics [2896]
- VHIO - Articles científics [846]
El ítem tiene asociados los siguientes ficheros de licencia: